vs

Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

BWX Technologies, Inc. is the larger business by last-quarter revenue ($860.2M vs $749.2M, roughly 1.1× CLOVER HEALTH INVESTMENTS, CORP.). BWX Technologies, Inc. runs the higher net margin — 10.6% vs 3.6%, a 7.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 26.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 12.4%).

BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

BWXT vs CLOV — Head-to-Head

Bigger by revenue
BWXT
BWXT
1.1× larger
BWXT
$860.2M
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+36.0% gap
CLOV
62.0%
26.1%
BWXT
Higher net margin
BWXT
BWXT
7.0% more per $
BWXT
10.6%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
12.4%
BWXT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BWXT
BWXT
CLOV
CLOV
Revenue
$860.2M
$749.2M
Net Profit
$91.2M
$27.3M
Gross Margin
Operating Margin
12.4%
3.6%
Net Margin
10.6%
3.6%
Revenue YoY
26.1%
62.0%
Net Profit YoY
20.7%
EPS (diluted)
$0.99
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BWXT
BWXT
CLOV
CLOV
Q1 26
$860.2M
$749.2M
Q4 25
$885.8M
$487.7M
Q3 25
$866.3M
$496.6M
Q2 25
$764.0M
$477.6M
Q1 25
$682.3M
$462.3M
Q4 24
$746.3M
$337.0M
Q3 24
$672.0M
$331.0M
Q2 24
$681.5M
$356.3M
Net Profit
BWXT
BWXT
CLOV
CLOV
Q1 26
$91.2M
$27.3M
Q4 25
$93.0M
$-49.3M
Q3 25
$82.1M
$-24.4M
Q2 25
$78.4M
$-10.6M
Q1 25
$75.5M
$-1.3M
Q4 24
$71.0M
$-22.1M
Q3 24
$69.5M
$-9.2M
Q2 24
$73.0M
$7.4M
Gross Margin
BWXT
BWXT
CLOV
CLOV
Q1 26
Q4 25
Q3 25
21.8%
Q2 25
25.1%
Q1 25
24.2%
Q4 24
Q3 24
24.4%
24.5%
Q2 24
24.7%
30.3%
Operating Margin
BWXT
BWXT
CLOV
CLOV
Q1 26
12.4%
3.6%
Q4 25
10.4%
-10.1%
Q3 25
13.1%
-4.9%
Q2 25
13.4%
-2.2%
Q1 25
14.2%
-0.3%
Q4 24
12.4%
-6.4%
Q3 24
14.4%
-2.7%
Q2 24
14.5%
2.0%
Net Margin
BWXT
BWXT
CLOV
CLOV
Q1 26
10.6%
3.6%
Q4 25
10.5%
-10.1%
Q3 25
9.5%
-4.9%
Q2 25
10.3%
-2.2%
Q1 25
11.1%
-0.3%
Q4 24
9.5%
-6.6%
Q3 24
10.3%
-2.8%
Q2 24
10.7%
2.1%
EPS (diluted)
BWXT
BWXT
CLOV
CLOV
Q1 26
$0.99
$0.05
Q4 25
$1.02
Q3 25
$0.89
Q2 25
$0.85
Q1 25
$0.82
Q4 24
$0.77
Q3 24
$0.76
Q2 24
$0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BWXT
BWXT
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$512.4M
$177.6M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$1.3B
$339.4M
Total Assets
$4.3B
$697.7M
Debt / EquityLower = less leverage
1.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BWXT
BWXT
CLOV
CLOV
Q1 26
$512.4M
$177.6M
Q4 25
$499.8M
$78.3M
Q3 25
$79.6M
Q2 25
$37.0M
Q1 25
$55.4M
Q4 24
$74.1M
$194.5M
Q3 24
$35.5M
$288.0M
Q2 24
$48.3M
$254.8M
Total Debt
BWXT
BWXT
CLOV
CLOV
Q1 26
$2.0B
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BWXT
BWXT
CLOV
CLOV
Q1 26
$1.3B
$339.4M
Q4 25
$1.2B
$308.7M
Q3 25
$1.2B
$340.9M
Q2 25
$1.2B
$344.2M
Q1 25
$1.1B
$336.1M
Q4 24
$1.1B
$341.1M
Q3 24
$1.1B
$342.2M
Q2 24
$998.5M
$324.9M
Total Assets
BWXT
BWXT
CLOV
CLOV
Q1 26
$4.3B
$697.7M
Q4 25
$4.3B
$541.0M
Q3 25
$3.8B
$559.7M
Q2 25
$3.7B
$575.0M
Q1 25
$3.1B
$583.7M
Q4 24
$2.9B
$580.7M
Q3 24
$2.9B
$653.0M
Q2 24
$2.8B
$674.2M
Debt / Equity
BWXT
BWXT
CLOV
CLOV
Q1 26
1.58×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BWXT
BWXT
CLOV
CLOV
Operating Cash FlowLast quarter
$92.6M
Free Cash FlowOCF − Capex
$50.1M
FCF MarginFCF / Revenue
5.8%
Capex IntensityCapex / Revenue
4.9%
Cash ConversionOCF / Net Profit
1.02×
TTM Free Cash FlowTrailing 4 quarters
$328.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BWXT
BWXT
CLOV
CLOV
Q1 26
$92.6M
Q4 25
$127.0M
$-66.9M
Q3 25
$143.2M
$12.1M
Q2 25
$159.0M
$5.4M
Q1 25
$50.6M
$-16.3M
Q4 24
$276.9M
$34.8M
Q3 24
$32.6M
$50.0M
Q2 24
$65.9M
$44.8M
Free Cash Flow
BWXT
BWXT
CLOV
CLOV
Q1 26
$50.1M
Q4 25
$56.8M
$-69.0M
Q3 25
$94.9M
$11.4M
Q2 25
$126.3M
$4.8M
Q1 25
$17.3M
$-16.5M
Q4 24
$224.4M
$33.3M
Q3 24
$-7.7M
$49.6M
Q2 24
$35.5M
$44.4M
FCF Margin
BWXT
BWXT
CLOV
CLOV
Q1 26
5.8%
Q4 25
6.4%
-14.1%
Q3 25
11.0%
2.3%
Q2 25
16.5%
1.0%
Q1 25
2.5%
-3.6%
Q4 24
30.1%
9.9%
Q3 24
-1.1%
15.0%
Q2 24
5.2%
12.5%
Capex Intensity
BWXT
BWXT
CLOV
CLOV
Q1 26
4.9%
Q4 25
7.9%
0.4%
Q3 25
5.6%
0.1%
Q2 25
4.3%
0.1%
Q1 25
4.9%
0.0%
Q4 24
7.0%
0.5%
Q3 24
6.0%
0.1%
Q2 24
4.5%
0.1%
Cash Conversion
BWXT
BWXT
CLOV
CLOV
Q1 26
1.02×
Q4 25
1.37×
Q3 25
1.74×
Q2 25
2.03×
Q1 25
0.67×
Q4 24
3.90×
Q3 24
0.47×
Q2 24
0.90×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons